Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
- Monday, September 26, 2022, 7:00
- Finance
- Add a comment
Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people…
About the Author
adminasapcorp has written 39386 stories on this site.